MichaelKrautMD

Oncology • Southfield, MI

Medical Director, Providence Cancer Institute

Join to view full profile

Dr. Kraut is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kraut's full profile

Already have an account?

Office
22301 Foster Winter Dr
200
Southfield, MI 48075
Phone+1 248-552-0620

Fax+1 248-552-0286

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1981 - 1983
Wayne State University School of MedicineResidency, Internal Medicine, 1978 - 1981
Wayne State University School of MedicineClass of 1978

Certifications & Licensure

MI State Medical License 1979 - 2024
IL State Medical License 1982 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer Start of enrollment: 2004 Nov 01
Unknown status
Phase 2
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

101 citations
Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment
Madhav Thambisetty, Yang An, Anna Kinsey, Deepthi Koka, Muzamil Saleem
Neuroimage. 2012-01-02
968 citations
Longitudinal Magnetic Resonance Imaging Studies of Older Adults: A Shrinking Brain
Susan M. Resnick, Dzung L. Pham, Michael A. Kraut, Alan B. Zonderman, Christos Davatzikos
The Journal of Neuroscience. 2003-04-15
55 citations
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
Lawrence E. Flaherty, G D O Bruce Redman, D O Silvana Martino, Michael Kraut, Manuel Valdivieso
Cancer. 1993-06-01